{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PSMA-617&page=2", "query": { "intervention": "PSMA-617", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PSMA-617&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T23:57:23.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04720157", "title": "An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "ARDT", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 1140, "start_date": "2021-06-09", "completion_date": "2027-02-11", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 70, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04720157" }, { "nct_id": "NCT06039371", "title": "Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Testosterone Cypionate", "type": "DRUG" }, { "name": "Radioconjugate", "type": "OTHER" }, { "name": "Dual X-ray Absorptiometry", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-PSMA-617", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 69, "start_date": "2024-05-21", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06039371" }, { "nct_id": "NCT06568562", "title": "XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2024-12-09", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06568562" }, { "nct_id": "NCT03042312", "title": "Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 71, "start_date": "2017-07-12", "completion_date": "2020-01-15", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042312" }, { "nct_id": "NCT07476001", "title": "Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate (Tc)", "type": "DRUG" }, { "name": "ADT with Luteinizing hormone-releasing hormone (LHRH) analog", "type": "DRUG" }, { "name": "PSMA-617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 12, "start_date": "2026-03-03", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07476001" }, { "nct_id": "NCT06379217", "title": "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neuroendocrine Prostate Cancer" ], "interventions": [ { "name": "[68Ga]Ga-PSMA-11", "type": "DRUG" }, { "name": "[68Ga]GA-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-PSMA-617", "type": "DRUG" }, { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "L-Lysine HCl-L-Arginine HCl, 2.5 %,", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "GnRH antagonists", "type": "DRUG" }, { "name": "Antiemetics & antinauseants", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 31, "start_date": "2024-07-29", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06379217" }, { "nct_id": "NCT06780670", "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Investigators choice of SoC", "type": "DRUG" }, { "name": "AAA817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 443, "start_date": "2025-02-27", "completion_date": "2033-07-19", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780670" }, { "nct_id": "NCT03545165", "title": "177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "177Lu-J591", "type": "DRUG" }, { "name": "68Ga-PSMA-HBED-CC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2018-04-18", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2021-08-24", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03545165" }, { "nct_id": "NCT06574880", "title": "STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm of Prostate", "Locally Advanced Prostate Cancer" ], "interventions": [ { "name": "Lu-PSMA-617", "type": "DRUG" }, { "name": "5-fraction Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Angela Y. Jia, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2025-05-13", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06574880" }, { "nct_id": "NCT05849298", "title": "A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasm" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "AAA517", "type": "DRUG" }, { "name": "Piflufolastat F 18", "type": "DRUG" }, { "name": "ARPI", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 49, "start_date": "2024-01-03", "completion_date": "2026-12-23", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-20T23:57:23.603Z", "location_count": 10, "location_summary": "Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05849298" } ] }